BOYA BIOLOGY: Approved for the supplemental application of intravenous immunoglobulin drug

BOYA BIOLOGY announced that the company recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, agreeing to increase the specification of intravenous human immunoglobulin to 5g/bottle and issuing the drug approval number. As of now, the total R&D investment for this drug is approximately 48.29 million yuan. This approval will further enrich the company's product pipeline and enhance its profitability and market competitiveness